By increasing the expression of epigenetically silent tumor antigens, azacitidine can enhance the GVL effect by activating CD8+ T cells directed toward many tumor antigens like melanoma-associated Ag 1, B melanoma antigen 1, and Wilm tumor Ag 1 (28). This evidence concerns the gene CD8A and neoplasm.